Skip to main content

Merck & Co., Inc. guidance

  • MRK · NYSE
  • Pharmaceuticals
  • S&P 500
$147.76+0.55%Close 13 Nov 2026 · Market value $361.6B

In its results release of 29 Oct 2026 (Q3 FY2026), Merck & Co., Inc. gave 5 forecasts in figures, among them revenue of $66.80B to $67.30B for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 29 Oct 2026

MeasurePeriodGuidanceAs stated
Revenue · RaisedFY2026$66.80B to $67.30B- Narrows and Raises the Midpoint of Worldwide Sales Range; Now Expects Sales To Be Between $66.8 Billion and $67.3 Billion
EPS · AdjustedFY2026$2.77 to $2.82Non-GAAP EPS $2.77 to $2.82
Gross margin · AdjustedFY202681%Non-GAAP Gross margin 81%
Operating expenses · AdjustedFY2026$42.40B to $42.90BNon-GAAP Operating expenses $42.4 billion to $42.9 billion
Tax rate · AdjustedFY202632% to 33%Non-GAAP Effective income tax rate 32.0% to 33.0%

Source: the company's earnings release.

Guidance against results above 1 · within 1 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$66.80B to $67.30BRaised 3 times—To come
EPS · AdjustedFY2026$2.77 to $2.82Raised twice, lowered once—To come
Gross margin · AdjustedFY202681%Lowered once—To come
Operating expenses · AdjustedFY2026$42.40B to $42.90BRaised twice—To come
Tax rate · AdjustedFY202632% to 33%Raised once, lowered once—To come
RevenueFY2025$64.50B to $65.00BNarrowed$65.01BWithin the range
RevenueFY2024$63.60B to $64.10BGiven once$64.17BAbove the range

MRK in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.